We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Prosonix Reports Positive Top-line Results from its Phase 2 Clinical Study with PSX1002

News   Jan 31, 2014

 
Prosonix Reports Positive Top-line Results from its Phase 2 Clinical Study with PSX1002
 
 
 

RELATED ARTICLES

Building Biologically Active Compounds Using Light

News

Researchers have now published a new method for building 3D scaffolds from flat aromatics using a photocatalyst.

READ MORE

Compound Targets Previously “Undruggable” STAT3 To Combat Cancer

News

A compound has been developed that targets transcription factor STAT3, offering a new approach to a previously “undruggable” target.

READ MORE

GW Pharmaceuticals Receives Positive NICE Recommendation for EPIDYOLEX (Cannabidiol)

News

GW Pharmaceuticals plc announces that two of its medicines, EPIDYOLEX (cannabidiol) oral solution and Sativex (nabiximols), have been recommended by the UK’s National Institute for Health and Care Excellence (NICE) to receive routine reimbursement from NHS England.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE